^
    Back
    Association details:
    Biomarker:EWSR1-TFCP2 fusion
    Cancer:Rhabdomyosarcoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Cold Spring Harb Mol Case Stud
    Title:

    EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas

    Published date:
    06/29/2022
    Excerpt:
    Here we describe a clinical case of intraosseous spindle cell RMS expressing EWSR1::TFCP2 fusion gene,...The tumor was extremely aggressive, showing resistance to polychemotherapy, radiation therapy, and crizotinib targeted therapy…
    DOI:
    10.1101/mcs.a006209